Endocrine ophthalmopathy

10 trials 1 recruiting MedDRA PT
10 Registered trials
1 Recruiting
3 Unique sponsors
5 Unique IMPs
10 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
L Oncology (ATC L) 1
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Kinase inhibitor 1 substance
FcRn antagonist 1 substance
Supportive / diluent 1 substance
Phase III: 8 Phase II: 2

Filter these 10 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 10 trials

Phase III

8 trials
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2023-509197-35-00 10 countries 2024 n=64
    Ended
  • Argenx Commercial
    EFGARTIGIMOD ALFA
    2023-509198-22-00 10 countries 2024 n=48
    Ended
  • Viridian Therapeutics Inc. Commercial
    VRDN-001
    2023-507217-10-00 6 countries 2024 n=170
    Ended
  • Viridian Therapeutics Inc. Commercial
    SODIUM CHLORIDE; VRDN-001
    2023-507350-33-00 8 countries 2024 n=76
    Ended
  • Viridian Therapeutics Inc. Commercial
    VRDN-001
    2023-507563-19-00 5 countries 2024 n=155
    Ended
  • Viridian Therapeutics Inc. Commercial
    VRDN-003
    2024-514972-42-00 5 countries 2025 n=54
    Recruiting
  • Viridian Therapeutics Inc. Commercial
    VRDN-003
    2024-514973-23-00 5 countries 2025 n=91
    Ended
  • Viridian Therapeutics Inc. Commercial
    VRDN-003
    2024-519417-57-00 4 countries 2025 n=140
    Ended

Phase II

2 trials
  • Sling Therapeutics Inc. Commercial
    LINSITINIB
    2022-502812-35-00 2 countries 2023 n=6
    Ended
  • Sling Therapeutics Inc. Commercial
    LINSITINIB
    2024-514449-12-00 2 countries 2022 n=18
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Viridian Therapeutics Inc. Commercial 6 Phase III 1
Sling Therapeutics Inc. Commercial 2 Phase II 0
Argenx Commercial 2 Phase III 0
New trials by year
2022
1
2023
1
2024
5
2025
3
← All indication landscapes